Splenomegaly

Phase 2 trials (13)

• busulfan
• lenalidomide
• eltrombopag
• obinutuzumab
• tacrolimus
• nivolumab
• levetiracetam
• ruxolitinib
• romiplostim
• cyclophosphamide
• mesna
• fludarabine
• rigosertib

Other trials (2)

• ritonavir
• sitagliptin

Organization Involved with Phase 4 Indications (1)

• Novartis

Organization Involved with Phase 3 Indications (1)

• Lihir Medical Centre

Organization Involved with Phase 2 Indications (6)

• Incyte
• Genentech
• Sanofi
• Onconova Therapeutics, Inc.
• Stanford University
• University of Texas at Houston

Organization Involved with Other Experimental Indications (2)

• National Cancer Institute (NCI)
• City of Hope National Medical Center